Robinhood, Applovin jump as S&P 500 reshuffle boosts index entrants
OrbiMed Advisors LLC, along with OrbiMed Capital GP IX LLC and OrbiMed Genesis GP LLC, reported purchasing shares of Shattuck Labs, Inc. (NASDAQ:STTK) on August 25, 2025. The transactions involved the acquisition of 6,306,127 shares of common stock at a price of $0.8677, totaling $5.47 million. The purchase price represents a significant discount to the current trading price of $1.01, with the stock showing strong momentum over the past month. According to InvestingPro data, analysts have set price targets ranging from $0.92 to $2.00 for the stock.
The purchases were made in connection with a securities purchase agreement, where OrbiMed acquired common stock and warrants.
Additionally, the report details the acquisition of Pre-Funded Warrants and Common Warrants, representing the right to buy additional shares of Shattuck Labs common stock.
In other recent news, Shattuck Labs announced the successful closing of a $103 million private placement led by OrbiMed, with participation from several investment firms. The proceeds are expected to fund operations into 2029 and support the advancement of SL-325, a DR3 blocking antibody, through various clinical milestones. Additionally, the FDA has cleared Shattuck Labs’ Investigational New Drug application for SL-325, allowing the company to proceed with a Phase 1 clinical study for inflammatory bowel disease. H.C. Wainwright has maintained a Neutral rating on the stock following this development. Meanwhile, Leerink Partners has lowered its price target for Shattuck Labs to $2.00 from $4.00 but continues to rate the stock as Outperform. Shattuck Labs also held its 2025 Annual Meeting of Stockholders, where all director nominees were elected, and the independent auditor was ratified. These developments reflect the company’s ongoing efforts to advance its pipeline and strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.